Editorial: Is TIPSS Implantation Effective in Patients With Portal Hypertensive Gastropathy? [0.03%]
editorial：食管胃静脉曲张患者行TIPS术的利与弊？
Marlene Reincke,Robert Thimme,Dominik Bettinger
Marlene Reincke
Letter: Using non-invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients [0.03%]
来信：利用非侵入性纤维化检测和新兴诊断技术提高MASLD患者肝纤维化分期的准确性
Wenjun Meng,Ping Yao,Yuan Dan
Wenjun Meng
Gustavo Ayares,Luis Antonio Díaz
Gustavo Ayares
Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply [0.03%]
编辑来信：allostatic负荷与炎症性肠病。作者回信
Jianhui Zhao,Erxu Xue,Zhanju Liu et al.
Jianhui Zhao et al.
Jeli Mendoza,James Irwin
Jeli Mendoza
Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non-Liver Malignancies in Hepatitis B Endemic Areas [0.03%]
乙肝流行地区肝癌与非肝癌免疫检查点抑制剂治疗的肝脏不良事件
Yi-Ping Hung,Pei-Chang Lee,Yen-Hwa Chang et al.
Yi-Ping Hung et al.
Background: Notable advances have been made in immune checkpoint inhibitors (ICIs) for cancer treatment. However, the adverse effects of ICIs, especially hepatotoxicity, remain a challenging problem. Whether patients in h...
Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real-World Multicentre Study in Japan [0.03%]
日本多中心溃疡性结肠炎患者Janus激酶抑制剂的真实世界疗效和安全性比较研究
Shintaro Akiyama,Hiromichi Shimizu,Akiko Tamura et al.
Shintaro Akiyama et al.
Background: Three Janus kinase (JAK) inhibitors are approved for ulcerative colitis (UC) in Japan. Aim: To compare the real-world effic...
Letter: Towards Better Intervention Strategies for MASLD and MetALD-What Are We Missing? Authors' Reply [0.03%]
来信：向更好的MASLD和MetALD干预策略迈进—我们遗漏了什么？作者回复
Yewan Park,Jooyi Jung,Gi-Ae Kim
Yewan Park
Serum Ferritin Levels and Liver-Related Events in Individuals With Steatotic Liver Disease: A Longitudinal Cohort Study [0.03%]
血清铁蛋白水平与肝脂肪变性患者的肝脏相关事件：一项纵向队列研究
Byeong Geun Song,Myung Ji Goh,Wonseok Kang et al.
Byeong Geun Song et al.
Background: Serum ferritin has been suggested as a potential biomarker associated with disease progression in metabolic dysfunction-associated steatotic liver disease (MASLD). ...